6) To provide rate-controlled drug action(various controlled-release Polyvinyl pyrrolidone tablets, capsules and suspensions) 7) To provide topical drug action from topical administration sites (ointments, creams, transdermal Polyvinyl acetate patches, ophthalmic, ear, and nasal preparations) PIROX CH OPIROX EAM 0.7 NET WT 30 gra
6) To provide rate-controlled drug action (various controlled-release tablets, capsules and suspensions) 7) To provide topical drug action from topical administration sites (ointments, creams, transdermal patches, ophthalmic, ear, and nasal preparations)
8)To provide for the insertion of a drug into one of the bodys orifices(e.g, rectal or vaginal suppositories) 9)To provide for the placement of drugs directly into the bloodstream or into NECTION US 12 mg/4 mL body's tissues(e.g. injections)
8) To provide for the insertion of a drug into one of the body’ s orifices (e.g., rectal or vaginal suppositories) 9) To provide for the placement of drugs directly into the bloodstream or into body’s tissues (e.g., injections)
lO) To provide for topical drug action throug. h Inhalation therapy (e.g, inhalants and inhalation aerosols)
10) To provide for topical drug action through inhalation therapy (e.g., inhalants and inhalation aerosols)
2. General considerations in dosage form design Desired features Drug release profile ■ Bioavailability Clinical effectiveness
2. General considerations in dosage form design Desired features ◼ Drug release profile ◼ Bioavailability ◼ Clinical effectiveness
Factors considered the nature of illness the manner in which it is treated ■age a anticipated condition of the patient Because they plays a role in dosage form design
Factors considered ◼ the nature of illness ◼ the manner in which it is treated ◼ age ◼ anticipated condition of the patient ◼ Because they plays a role in dosage form design